Supernus Pharmaceuticals, Inc. (SUPN) Lifted to “Buy” at Zacks Investment Research

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday, July 13th. The brokerage currently has a $49.00 price objective on the specialty pharmaceutical company’s stock. Zacks Investment Research‘s price target points to a potential upside of 18.36% from the stock’s current price.

According to Zacks, “Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. “

Several other research firms have also recently issued reports on SUPN. Cantor Fitzgerald raised their price objective on shares of Supernus Pharmaceuticals from $34.00 to $49.00 and gave the stock a “buy” rating in a research report on Wednesday, July 5th. Jefferies Group LLC lifted their price target on shares of Supernus Pharmaceuticals from $45.00 to $51.00 and gave the company a “buy” rating in a research report on Wednesday, June 28th. Stifel Nicolaus raised their price objective on shares of Supernus Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, April 3rd. Cowen and Company raised their price objective on shares of Supernus Pharmaceuticals from $31.00 to $34.00 and gave the company an “outperform” rating in a research note on Thursday, May 11th. Finally, Piper Jaffray Companies raised shares of Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $30.00 to $44.00 in a research note on Thursday, June 1st. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $48.43.

Supernus Pharmaceuticals (SUPN) traded up 2.60% during mid-day trading on Thursday, reaching $41.40. 794,247 shares of the company’s stock traded hands. The firm’s 50-day moving average price is $42.53 and its 200 day moving average price is $34.00. Supernus Pharmaceuticals has a one year low of $17.25 and a one year high of $44.95. The firm has a market cap of $2.10 billion, a price-to-earnings ratio of 20.89 and a beta of 1.31.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 EPS for the quarter, beating the Zacks’ consensus estimate of $0.24 by $0.08. The business had revenue of $75.83 million during the quarter, compared to analysts’ expectations of $68.54 million. Supernus Pharmaceuticals had a net margin of 41.10% and a return on equity of 30.73%. On average, equities analysts forecast that Supernus Pharmaceuticals will post $1.04 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.com-unik.info/2017/08/11/supernus-pharmaceuticals-inc-supn-rating-increased-to-buy-at-zacks-investment-research-updated-updated-updated.html.

In related news, VP Padmanabh P. Bhatt sold 5,500 shares of the business’s stock in a transaction dated Thursday, May 25th. The shares were sold at an average price of $34.90, for a total value of $191,950.00. Following the sale, the vice president now directly owns 43,887 shares in the company, valued at approximately $1,531,656.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, VP Padmanabh P. Bhatt sold 2,500 shares of the business’s stock in a transaction dated Friday, May 26th. The stock was sold at an average price of $35.90, for a total transaction of $89,750.00. Following the completion of the sale, the vice president now owns 37,500 shares in the company, valued at $1,346,250. The disclosure for this sale can be found here. Insiders have sold a total of 24,291 shares of company stock worth $962,766 over the last 90 days. Insiders own 6.70% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of SUPN. BlackRock Inc. increased its position in Supernus Pharmaceuticals by 0.5% in the second quarter. BlackRock Inc. now owns 6,727,641 shares of the specialty pharmaceutical company’s stock worth $289,962,000 after buying an additional 31,331 shares in the last quarter. Vanguard Group Inc. increased its position in Supernus Pharmaceuticals by 39.1% in the second quarter. Vanguard Group Inc. now owns 3,500,535 shares of the specialty pharmaceutical company’s stock worth $150,873,000 after buying an additional 984,200 shares in the last quarter. Bank of New York Mellon Corp increased its position in Supernus Pharmaceuticals by 4.9% in the first quarter. Bank of New York Mellon Corp now owns 1,668,864 shares of the specialty pharmaceutical company’s stock worth $52,236,000 after buying an additional 78,084 shares in the last quarter. Ranger Investment Management L.P. increased its position in Supernus Pharmaceuticals by 2.8% in the first quarter. Ranger Investment Management L.P. now owns 1,482,535 shares of the specialty pharmaceutical company’s stock worth $46,403,000 after buying an additional 40,131 shares in the last quarter. Finally, Rice Hall James & Associates LLC increased its position in Supernus Pharmaceuticals by 24.5% in the second quarter. Rice Hall James & Associates LLC now owns 1,361,373 shares of the specialty pharmaceutical company’s stock worth $58,675,000 after buying an additional 267,971 shares in the last quarter. 94.39% of the stock is owned by institutional investors.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

What are top analysts saying about Supernus Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Supernus Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit